RxDoctor Payments Data

Jeffrey Brown, DO

Cardiovascular Disease · Washington, MONPI 1942403399

Payments from drug & device makers

$3,559in general payments, 2019–2025

Across 194 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$444
  • Johnson & Johnson$420
  • Boehringer Ingelheim$366
  • Novartis$364
  • Novo Nordisk$302
  • Pfizer$219
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,46097%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,559 in reported general payments places this provider in the 55th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$182,741
Medicare patients
1,213
Services billed
2,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,314$1,205,792
XareltoRivaroxaban273$272,775
Repatha SureclickEvolocumab313$246,470
EntrestoSacubitril/Valsartan70$78,736
JardianceEmpagliflozin83$78,587
Praluent PenAlirocumab53$29,392
MultaqDronedarone Hcl12$13,874
VascepaIcosapent Ethyl34$13,364
BrilintaTicagrelor21$12,202
Rosuvastatin Calcium1,092$12,021
Bumetanide384$11,239
Atorvastatin Calcium1,170$10,690
Repatha SyringeEvolocumab13$7,499
Losartan Potassium928$6,370
SotalolSotalol Hcl290$5,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$219$1,205,7921,314 claims
Johnson & JohnsonXarelto$420$272,775273 claims
NovartisEntresto$364$78,73670 claims
Boehringer IngelheimJardiance$366$78,58783 claims
AstraZenecaBrilinta$22$12,20221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →